Haisco Pharmaceutical Group Co., Ltd.
002653.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$68.34B
Close$
$-21.08
135.4% downside
Current Fair Value
135.4% downsideOvervalued by 135.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $68.34 Billion |
|---|---|
| Enterprise Value | $68.87 Billion |
| Dividend Yield | $0.27 (1.30%) |
| Earnings per Share | $0.23 |
| Beta | -0.22 |
| Outstanding Shares | 1,119,917,970 |
Return
| Return on Equity | 20.39% |
|---|---|
| Return on Assets | 12.47% |
| Return on Invested Capital | 16.89% |
Valuation & Multiples
| P/E Ratio | 69.49 |
|---|---|
| PEG | 26.64 |
| Price to Sales | 14.9 |
| Price to Book Ratio | 14.9 |
| Enterprise Value to Revenue | 12.56 |
| Enterprise Value to EBIT | 72.54 |
| Enterprise Value to Net Income | 70 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.49 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.53 B
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.38
Average shareholder expectationRevenue Estimate
$2.04 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Haisco Pharmaceutical Group Co., Ltd.
5,597 employees
CEO: Pangke Yan Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, i...